Major Histocompatibility Complex class I and II peptide-binding grooves (MHC I/II PBG)

The MHC class I and II peptide-binding grooves are specialized structural domains on the surface of Major Histocompatibility Complex (MHC) molecules, also known as Human Leukocyte Antigens (HLAs) in humans. These grooves are responsible for capturing and displaying short peptide fragments (antigens) derived from intracellular or extracellular proteins to T-cell receptors (TCRs). MHC class I grooves are typically closed at both ends and bind 8-10 amino acid peptides, while MHC class II grooves are open-ended, accommodating longer peptides of 13-25 amino acids. This interaction is the fundamental step in initiating adaptive immune responses, allowing the immune system to distinguish between self and non-self (pathogenic or cancerous) antigens. In therapeutic contexts, these grooves are targeted by drugs like glatiramer acetate, which competitively binds to MHC class II grooves to modulate autoimmune responses in multiple sclerosis. Additionally, peptide vaccines and TCR-mimetic antibodies leverage the specificity of these grooves to direct immune attacks against tumors or viruses. The high polymorphism of the genes encoding these grooves presents a significant challenge for drug development, as therapeutic efficacy is often restricted to specific HLA alleles.

Other names

Antigen-binding cleftMHC binding pocketHLA peptide-binding grooveMHC-peptide binding siteMHC antigen-binding groove

Drugs targeting the MHC peptide-binding grooves typically work through competitive inhibition, where a therapeutic agent binds to the groove to prevent the presentation of auto-antigens, or through direct antigen presentation, where synthetic peptides are loaded into the groove to prime T cells against specific pathogens or tumors.